Vanguard Group’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

Vanguard Group’s Portfolio PXMD Stock Details PXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,233	Closed	-$15.7K	–	4572
2023 Q3	$15.7K	Hold	3,233	–	–	﹤0.01%	4510
2023 Q2	$43.2K	Hold	3,233	–	–	﹤0.01%	4472
2023 Q1	$105K	Buy	+3,233	New	+$130K	﹤0.01%	4401

Other funds holding PXMD

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's PXMD Position: Q4 2023 in Review

Vanguard Group sold out of PaxMedica, Inc. Common Stock (PXMD) in Q4 2023, closing a stake of 3,233 shares — an estimated $15.7K sold.

Vanguard Group first reported a position in PXMD in Q1 2023 and held it in 3 quarters. The position peaked at $105K in Q1 2023. 9 funds tracked by Wall St. Rank hold PXMD as of Q4 2023.

Vanguard Group reported no remaining PaxMedica, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Vanguard Group sold 3,233 PaxMedica, Inc. Common Stock shares in Q4 2023, an estimated $15.7K.
Vanguard Group first reported a position in PaxMedica, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
Vanguard Group's PaxMedica, Inc. Common Stock position peaked at $105K in Q1 2023.
9 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.